\$40.00 635849

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Berlex Laboratories, Inc.	02/15/2007

RECEIVING PARTY DATA

Name:	Xanthus Pharmaceuticals, Inc.	
Street Address:	300 Technology Square	
City:	Cambridge	
State/Country:	MASSACHUSETTS	
Postal Code:	01238	

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	6358491

CORRESPONDENCE DATA

Fax Number: (703)243-6314

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 703-243-6333

Email: kelly@mwzb.com

Correspondent Name: John A. Sopp

Address Line 1: 2200 Clarendon Blvd

Address Line 2: Suite 1400

Address Line 4: Arlington, VIRGINIA 22201

ATTORNEY DOCKET NUMBER:	XANTHUS-0001-X
NAME OF SUBMITTER:	John A. Sopp

Total Attachments: 3

source=PatentAssignmentCoverSheetBerlex-4-19-07#page1.tif

source=BerlexAssignment-4-19-07#page1.tif source=BerlexAssignment-4-19-07#page2.tif

PATENT REEL: 019181 FRAME: 0434

Form PTO-1595				
RECORDATION FOR (Rev. 10/02)	M COVER SHEET U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office			
OMB No. 0651-0027 (exp. 6/30/2005)				
	TS ONLY			
	rks: Please record the attached documents or copy thereof.			
1. Name of conveying party(ies):	2. Name and address of receiving party(ies):			
Berlex Laboratories, Inc. of Montville, New Jersey, USA				
a Delaware Corporation	Name: Xanthus Pharmaceuticals, Inc.			
	Internal Address:			
Additional name(s) of conveying party(ies) attached?				
3. Nature of Conveyance:				
or conveyance.				
	Street Address: 300 Technology Square			
Security Agreement Change of Name				
☐ Other	City: Cambridge State: MA Zip:			
Execution Date: February 15, 2007				
	No additional names(s) or address(es) attached 🔲 Yes 🗵 No			
4. Application number(s) or patent number(s):	To additional times(s) or add ess(es) assessed 💆 235 💆 2			
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No.(s) B. Patent No.(s) 6,358,491				
Additional numbers attac	hed? 🗌 Yes 🔀 No			
5. Name and address of party to whom correspondence	6. Total number of applications and patents involved:			
concerning document should be mailed:				
Name MARKENI MURITE ZELANIO	7. Total fee (37CFR 3.41) \$40.00			
Name: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.	Enclosed			
Address: Arlington Court Plaza I	Authorized to be charged to deposit account			
Suite 1400 2200 Clarendon BLVD.	8. DEPOSIT ACCOUNT NO. 13-3402			
Arlington, VA 22201				
, , , , , , , , , , , , , , , , , , ,	(Attach duplicate copies of this page if paying by deposit account)			
DO NOT USE THIS SPACE				
9. Statement and Signature.				
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.				
John A. Sopp, Reg. No. 33,103/John A. SignatureNames of Person SigningSignature	Sopp/ April 19, 2007 Date			
Total number of pages including cover speet, attachments, and doc	uments 3			

Attorney Docket No. XANTHIUS-0001 X

ASSIGNMENT

WHEREAS,

Berlex Laboratories, Inc.

of Montville, New Jersey, USA

a Delaware Corporation

hereinafter referred to as the ASSIGNOR, is the current owner of the entire right, title and interest in and to the following U.S. Letters Patent and/or U.S. applications, the inventions covered thereby, the application(s) from which said Letters Patent issued and all U.S. and foreign and international treaty priority rights claimed therein or corresponding thereto:

US Patent No. 6,358,491

as well as all continuation and divisional applications claiming benefit of any of said applications,

AND WHEREAS,

Xanthus Pharmaceuticals, Inc.

300 Technology Square

Cambridge, Massachusetts, USA

hereinafter referred to as ASSIGNEE, is desirous of acquiring the entire right, title and interest in and to said inventions, said Letters Patent including any and all renewals, reissues and prolongations thereof, and said applications, including the right to sue under said Letters Patent and applications for infringement occurring herebefore.

NOW, THIS WITNESSETH that for good and valuable consideration, the receipt whereof is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, its assigns and legal representatives, the entire and exclusive right, title and interest in and to said inventions, said Letters Patent including any and all renewals, reissues and prolongations thereof, and said applications, including the right to sue under said Letters Patents and applications, for infringement occurring herebefore, ASSIGNEE and its assigns and legal representatives to have, hold, exercise, and enjoy said inventions, Letters Patent including any

PATENT REEL: 019181 FRAME: 0436 and all renewals, reissues, and prolongations thereof, and said applications, with all the rights, powers, privileges, and advantages in anywise arising from or appertaining thereto, for and during the term or terms of said Letters Patent and any future patents issuing from said applications, including any and all renewals, reissues, and prolongations thereof, for the use and benefit of ASSIGNEE and its assigns and legal representatives, in as ample and beneficial a manner to all intents and purposes as the ASSIGNOR might or could have held and enjoyed the same, if this assignment had not been made.

BAYER SCHERING PHARMA AG

Berlex Laboratories, Inc.

Date: February 15, 2007

By:

Name: Robert A. Chabora

Title: Executive Vice President

Reviewed

| Finance:

PATENT,

REEL: 019181 FRAME: 0437